WO2020139163A3 - Combination of antiviral agents - Google Patents

Combination of antiviral agents Download PDF

Info

Publication number
WO2020139163A3
WO2020139163A3 PCT/RU2019/001031 RU2019001031W WO2020139163A3 WO 2020139163 A3 WO2020139163 A3 WO 2020139163A3 RU 2019001031 W RU2019001031 W RU 2019001031W WO 2020139163 A3 WO2020139163 A3 WO 2020139163A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
mammal
agent
treatment
group
Prior art date
Application number
PCT/RU2019/001031
Other languages
French (fr)
Russian (ru)
Other versions
WO2020139163A2 (en
Inventor
Роберт Шалвович БИБИЛАШВИЛИ
Александр Васильевич КОНОНОВ
Алексей Викторович Кравченко
Анастасия Львовна ХАНДАЖИНСКАЯ
Алина Руслановна СИМОНЯН
Original Assignee
Общество С Ограниченной Ответственностью "Пролонгированные Лекарства"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" filed Critical Общество С Ограниченной Ответственностью "Пролонгированные Лекарства"
Priority to KR1020217023854A priority Critical patent/KR20210119408A/en
Priority to BR112021017961A priority patent/BR112021017961A2/en
Priority to CN201980093074.5A priority patent/CN113473994A/en
Publication of WO2020139163A2 publication Critical patent/WO2020139163A2/en
Publication of WO2020139163A3 publication Critical patent/WO2020139163A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The group of inventions relates to the field of medicine and the pharmaceutical industry, and specifically to a combination for treatment of an HIV infection, comprising (i) an ammonia salt of 5-aminocarbonylphosphonate-3-azido-3-desoxythymidine and (ii) an analogue of cytidine selected from emtricitabine and lamivudine in a mass ratio of agent (i) to agent (ii) of from 250:1 to 1:250; to a kit which includes said combination and instructions for use thereof; and also to a method for treating an HIV infection in a mammal, including a human, by administering a therapeutically effective amount of the proposed combination to the mammal in need thereof. The group of inventions broadens the range of combined antiviral preparations for treating HIV infections and also increases the effectiveness of such treatment.
PCT/RU2019/001031 2018-12-27 2019-12-26 Combination of antiviral agents, kit and treatment method based on same WO2020139163A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020217023854A KR20210119408A (en) 2018-12-27 2019-12-26 antiviral compound
BR112021017961A BR112021017961A2 (en) 2018-12-27 2019-12-26 Combination of antiviral agents, kit and treatment method based on them
CN201980093074.5A CN113473994A (en) 2018-12-27 2019-12-26 Combination of antiviral agents, kits and methods of treatment based thereon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018147078A RU2726210C2 (en) 2018-12-27 2018-12-27 Combination of antiviral agents, kit and method of treatment based thereon
RU2018147078 2018-12-27

Publications (2)

Publication Number Publication Date
WO2020139163A2 WO2020139163A2 (en) 2020-07-02
WO2020139163A3 true WO2020139163A3 (en) 2020-08-27

Family

ID=71130174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2019/001031 WO2020139163A2 (en) 2018-12-27 2019-12-26 Combination of antiviral agents, kit and treatment method based on same

Country Status (5)

Country Link
KR (1) KR20210119408A (en)
CN (1) CN113473994A (en)
BR (1) BR112021017961A2 (en)
RU (1) RU2726210C2 (en)
WO (1) WO2020139163A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022237405A1 (en) * 2021-03-15 2023-11-02 Transposon Therapeutics, Inc. Line-1 inhibitors to treat cns and systemic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2331420C2 (en) * 2005-12-08 2008-08-20 Роберт Шалвович Бибилашвили Antiviral agent (versions) and treatment method based on it
RU2441016C1 (en) * 2010-05-28 2012-01-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" 5'-aminocarbonylphophonate 3'-azido-3'-deoxythymidine salts being selective inhibitors of human immunodeficiency virus hiv-1
US8716264B2 (en) * 2003-01-14 2014-05-06 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20140193491A1 (en) * 2011-05-30 2014-07-10 Cipla Limited Pharmaceutical antiretroviral composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2446169C2 (en) * 2010-05-28 2012-03-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Method of producing 5'-aminocarbonylphosphonates of nucleosides and method of producing acyl chloride of trimethylsilyl ether of ethoxycarbonylphosphonic acid
KR101976231B1 (en) * 2011-10-14 2019-05-07 자크리토에 악치오네르노에 오브쉐스토보 ＂프로이즈보드스트벤노-콤머체스카야 아쏘치아치야 아즈트＂ Salts of carbamoyl phosphonic acid esters which act as selective inhibitors of human immunodeficiency virus hiv-1 production
CN104884063A (en) * 2012-10-23 2015-09-02 西普拉有限公司 Pharmaceutical antiretroviral composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716264B2 (en) * 2003-01-14 2014-05-06 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
RU2331420C2 (en) * 2005-12-08 2008-08-20 Роберт Шалвович Бибилашвили Antiviral agent (versions) and treatment method based on it
RU2441016C1 (en) * 2010-05-28 2012-01-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" 5'-aminocarbonylphophonate 3'-azido-3'-deoxythymidine salts being selective inhibitors of human immunodeficiency virus hiv-1
US20140193491A1 (en) * 2011-05-30 2014-07-10 Cipla Limited Pharmaceutical antiretroviral composition

Also Published As

Publication number Publication date
RU2726210C2 (en) 2020-07-09
KR20210119408A (en) 2021-10-05
RU2018147078A (en) 2020-06-29
BR112021017961A2 (en) 2021-12-28
WO2020139163A2 (en) 2020-07-02
CN113473994A (en) 2021-10-01
RU2018147078A3 (en) 2020-06-29

Similar Documents

Publication Publication Date Title
HRP20191957T1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CY1118059T1 (en) ANTIBODY COMPOSITIONS BASED ON FAT FOR TREATMENT OF PULMONARY INFECTIONS
CR20220675A (en) 1'-cyano nucleoside analogs and uses thereof
MX2019012884A (en) Combination therapy.
MX2012007410A (en) Novel antiviral compounds.
NO20076219L (en) Pharmaceutical formulation with apomorphine for buccal administration
RU2007104774A (en) COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASES INHIBITORS
WO2018089328A8 (en) Treatment of cns diseases with sgc stimulators
CO2021007648A2 (en) 3,3- Difluoroallylamines or salts thereof and pharmaceutical compositions comprising them
MD20190018A2 (en) Composition, in particular a preventive and curative pharmaceutical composition, made from peroxometallate
MX2022002196A (en) Niclosamide delayed-release composition and antiviral use thereof.
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2021010145A (en) Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases.
MX2018000240A (en) Methods for treating hcv.
HRP20230300T1 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
WO2020139163A3 (en) Combination of antiviral agents
MX2020008360A (en) Crystalline form of bictegravir sodium.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
Tobie The trypanocidal effect of nucleocidin in vivo
MX2021002936A (en) Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease.
WO2014193269A3 (en) Diindolylmethane-based medicinal agent and use thereof to treat influenza and viral respiratory infections
HUP0402062A2 (en) Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them
GEP20227432B (en) Therapy of high-risk human papillomavirus infections
EA202091903A1 (en) CRYSTAL FORM OF BITEGAVIR-SODIUM

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021017961

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021017961

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, RELATORIO DESCRITIVO E DESENHOS, SE HOUVER, CONFORME CONSTA NO DEPOSITO INTERNACIONAL INICIAL PCT/RU2019/001031 DE 26/12/2019, POIS O MESMO NAO FOI APRESENTADO ATE O MOMENTO.

ENP Entry into the national phase

Ref document number: 112021017961

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210910

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04.11.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19903163

Country of ref document: EP

Kind code of ref document: A2